Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6020968 | Journal of Neuroimmunology | 2012 | 5 Pages |
Abstract
Aβ vaccination has been shown to induce remarkable clearance of brain amyloid plaques in mouse models of Alzheimer's disease (AD). However, the extent to which antibody-mediated Aβ clearance is affected by predominant formation of Aβ42 over Aβ40 is unclear. Here we demonstrate for the first time that in a mouse model carrying the human APP mutations KM670/671NL and the human PS1 mutation P166L, Aβ vaccination does not result in plaque clearance. This was in spite of the strong T- and B-cell immune responses evoked under the DR1501 genetic background and the activation of microglia at sites of Aβ plaques. Our findings suggest the existence of antibody-resistant forms of Aβ deposits in the brain consisting of primarily Aβ42, and shed light on the mechanisms of antibody-dependent amyloid clearance as well as novel therapeutic strategies for AD.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Anna Nemirovsky, Jenny Shapiro, Rona Baron, Alex Kompaniets, Alon Monsonego,